# MNDA

## Overview
The MNDA gene encodes the myeloid cell nuclear differentiation antigen, a protein primarily expressed in myeloid cells and involved in the regulation of transcription and apoptosis. As a member of the PYHIN protein family, MNDA is characterized by the presence of a PYRIN domain and one or two HIN-200 domains, which facilitate its role in protein interactions and nucleic acid binding (Bottardi2024MNDA). The protein is predominantly localized in the nucleus, where it functions as a transcription factor, influencing the expression of genes critical for cell survival and immune response (Bottardi2024MNDA). MNDA's involvement in apoptosis and inflammation highlights its significance in immune regulation and its potential implications in various hematological disorders and inflammatory conditions (Bottardi2024MNDA; Briggs2006Dysregulated).

## Structure
The myeloid nuclear differentiation antigen (MNDA) is a member of the PYHIN protein family, characterized by a conserved domain architecture that includes a PYRIN domain (PYD) and one or two HIN-200 domains. The PYD is involved in protein oligomerization and signaling pathways related to apoptosis, cell cycle, and inflammation (Bottardi2024MNDA). The HIN-200 domain, highly conserved among mammals, is involved in protein interactions and nucleic acid binding, containing a tandem pair of beta barrels or oligonucleotide/oligosaccharide binding (OB) folds formed by 70-80 amino acid residues (Li2014Purification; Bottardi2024MNDA).

MNDA also contains an intrinsically disordered region (IDR) between the PYD and HIN-200 domains, which can interact with DNA and RNA molecules, influencing nucleic acid binding properties (Bottardi2024MNDA). The protein has a putative nuclear localization signal (NLS), suggesting its primary localization in the nucleus of leukocytes (Bottardi2024MNDA). MNDA undergoes caspase-dependent cleavage, separating its PYD and HIN-200 domains into different fragments, which may facilitate interactions necessary for inflammasome formation (Bottardi2024MNDA). The protein is primarily monomeric and composed of beta-sheets (Li2014Purification).

## Function
The MNDA (myeloid cell nuclear differentiation antigen) gene encodes a protein that plays a significant role in transcriptional regulation and apoptosis control in leukocytes. MNDA is predominantly localized in the nucleolus and acts as a transcription factor, particularly in monocytes, where it binds to chromatin and modulates the recruitment of RNA polymerase II to specific genes such as MCL1, BCL2, and IRF7, which are crucial for cell survival and immune response (Bottardi2024MNDA). MNDA interacts with proteins like CDK9 and HEXIM1 to control gene expression, affecting transcriptional elongation by reducing RNA polymerase II processivity and influencing the reloading of P-TEFb and Pol II at transcription start sites (Bottardi2024MNDA).

In healthy human cells, MNDA is involved in the regulation of the immune response, particularly in the context of inflammation and apoptosis. It undergoes caspase-dependent cleavage, resulting in its relocalization from the nucleus to the cytoplasm, correlating with the induction of effector caspases and cell death in neutrophils. This process is important for controlling the release of pro-inflammatory molecules and preventing tissue injury (Bottardi2024MNDA). MNDA also influences the expression of anti-apoptotic factors like MCL-1 and BCL-2, promoting apoptosis in certain cell types (Bottardi2024MNDA).

## Clinical Significance
The MNDA gene plays a significant role in various hematological disorders and inflammatory conditions due to its involvement in transcriptional regulation and apoptosis control. In chronic lymphocytic leukemia (CLL), MNDA expression levels inversely correlate with the expression of anti-apoptotic proteins MCL-1 and BCL-2. Higher MNDA expression is associated with better clinical outcomes, such as longer progression-free survival, suggesting its potential as a prognostic marker in CLL (Bottardi2020MNDA).

In myelodysplastic syndromes (MDS), reduced MNDA expression is linked to increased sensitivity of hematopoietic progenitor cells to apoptosis, particularly through the TRAIL pathway. This down-regulation may contribute to the cytopenias characteristic of MDS (Briggs2006Dysregulated). MNDA's role in apoptosis is also evident in sepsis, where its expression influences neutrophil apoptosis by promoting the degradation of MCL-1 (FotouhiArdakani2010Role).

MNDA expression is used diagnostically to differentiate between certain lymphomas. It is highly expressed in marginal zone lymphomas (MZLs) but not in follicular lymphomas (FL), aiding in their distinction (Wang2018IRTA1). These findings underscore MNDA's clinical significance in diagnosing and understanding the progression of various hematological and inflammatory diseases.

## Interactions
MNDA (myeloid cell nuclear differentiation antigen) is known to interact with several proteins and nucleic acids, playing a significant role in gene transcription regulation. One of its primary interactions is with the transcription factor YY1. MNDA enhances YY1's DNA binding ability by increasing the association rate and reducing the dissociation rate of YY1 with its target DNA. This interaction involves the formation of a ternary complex with YY1 and DNA, which is characteristic of inhibition by quenching (Xie1998Human). The interaction site on MNDA for YY1 binding is mapped to amino acids 53 to 150, which includes a basic amphipathic alpha helical region and an imperfect leucine zipper, indicative of protein binding (Xie1998Human).

MNDA also interacts with other nuclear proteins such as nucleolin and nucleophosmin (NPM/B23), suggesting its role as a coregulator in gene expression (Xie1998Human). In addition, MNDA is involved in the regulation of apoptosis through its interaction with the anti-apoptotic factor MCL-1, influencing MCL-1 turnover and the intrinsic apoptotic pathway in neutrophils (Milot2012Myeloid). These interactions highlight MNDA's multifaceted role in cellular processes, particularly in hematopoietic cells.


## References


[1. (Li2014Purification) He Li, Zhi-Xin Wang, and Jia-Wei Wu. Purification, characterization and docking studies of the hin domain of human myeloid nuclear differentiation antigen (mnda). Biotechnology Letters, 36(5):899–905, February 2014. URL: http://dx.doi.org/10.1007/s10529-013-1432-y, doi:10.1007/s10529-013-1432-y. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10529-013-1432-y)

[2. (Milot2012Myeloid) Eric Milot, Nasser Fotouhi-Ardakani, and János G. Filep. Myeloid nuclear differentiation antigen, neutrophil apoptosis and sepsis. Frontiers in Immunology, 2012. URL: http://dx.doi.org/10.3389/fimmu.2012.00397, doi:10.3389/fimmu.2012.00397. This article has 33 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2012.00397)

[3. (Xie1998Human) Jingping Xie, Judith A. Briggs, and Robert C. Briggs. Human hematopoietic cell specific nuclear protein mnda interacts with the multifunctional transcription factor yy1 and stimulates yy1 dna binding. Journal of Cellular Biochemistry, 70(4):489–506, September 1998. URL: http://dx.doi.org/10.1002/(SICI)1097-4644(19980915)70:4<489::AID-JCB6>3.0.CO;2-F, doi:10.1002/(sici)1097-4644(19980915)70:4<489::aid-jcb6>3.0.co;2-f. This article has 56 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/(SICI)1097-4644(19980915)70:4)

[4. (Wang2018IRTA1) Zhen Wang and James R Cook. Irta1 and mnda expression in marginal zone lymphoma. American Journal of Clinical Pathology, 151(3):337–343, October 2018. URL: http://dx.doi.org/10.1093/ajcp/aqy144, doi:10.1093/ajcp/aqy144. This article has 33 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/ajcp/aqy144)

[5. (FotouhiArdakani2010Role) Nasser Fotouhi-Ardakani, Driss El Kebir, Natacha Pierre-Charles, Lili Wang, Stephane P. Ahern, János G. Filep, and Eric Milot. Role for myeloid nuclear differentiation antigen in the regulation of neutrophil apoptosis during sepsis. American Journal of Respiratory and Critical Care Medicine, 182(3):341–350, August 2010. URL: http://dx.doi.org/10.1164/rccm.201001-0075oc, doi:10.1164/rccm.201001-0075oc. This article has 39 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1164/rccm.201001-0075oc)

[6. (Bottardi2024MNDA) Stefania Bottardi, Taylorjade Layne, Ailyn C. Ramòn, Norreen Quansah, Hugo Wurtele, El Bachir Affar, and Eric Milot. Mnda, a pyhin factor involved in transcriptional regulation and apoptosis control in leukocytes. Frontiers in Immunology, April 2024. URL: http://dx.doi.org/10.3389/fimmu.2024.1395035, doi:10.3389/fimmu.2024.1395035. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2024.1395035)

[7. (Bottardi2020MNDA) Stefania Bottardi, Romain Guieze, Vincent Bourgoin, Nasser Fotouhi-Ardakani, Aurore Dougé, Anaïs Darracq, Yahia A. Lakehal, Marc G. Berger, Luigina Mollica, Jacques-Olivier Bay, James G. Omichinski, and Eric Milot. Mnda controls the expression of mcl-1 and bcl-2 in chronic lymphocytic leukemia cells. Experimental Hematology, 88:68-82.e5, August 2020. URL: http://dx.doi.org/10.1016/j.exphem.2020.07.004, doi:10.1016/j.exphem.2020.07.004. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.exphem.2020.07.004)

[8. (Briggs2006Dysregulated) Robert C. Briggs, Keith E. Shults, Leanne A. Flye, Sara A. McClintock-Treep, Madan H. Jagasia, Stacey A. Goodman, Fouad I. Boulos, James W. Jacobberger, Greg T. Stelzer, and David R. Head. Dysregulated human myeloid nuclear differentiation antigen expression in myelodysplastic syndromes: evidence for a role in apoptosis. Cancer Research, 66(9):4645–4651, May 2006. URL: http://dx.doi.org/10.1158/0008-5472.CAN-06-0229, doi:10.1158/0008-5472.can-06-0229. This article has 53 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.CAN-06-0229)